e-Therapeutics’ strategy has evolved, shifting from investment into its proprietary discovery platform to commercialisation of its 12 preclinical assets and the platform itself. Out-licensing and collaborations, potentially in the next 12-24 months, should validate the platform and fund future discovery work and identification of the next wave of lead candidates.
19 May 2016
Courting commercialisation partners
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Courting commercialisation partners
e-Therapeutics plc (ETX:LON) | 10.0 0 (-2.5%) | Mkt Cap: 58.1m
- Published:
19 May 2016 -
Author:
Lala Gregorek -
Pages:
12
e-Therapeutics’ strategy has evolved, shifting from investment into its proprietary discovery platform to commercialisation of its 12 preclinical assets and the platform itself. Out-licensing and collaborations, potentially in the next 12-24 months, should validate the platform and fund future discovery work and identification of the next wave of lead candidates.